ThromboGenics says that a mid-stage trial of microplasmin demonstrated positive results for a back-of-the-eye disease. And researchers said that the safety profile of the drug was so good that they decided to recruit an additional 15 patients to test a higher dosage of the drug. They will present their data at the annual meeting of the American Society of Retina Specialists.
- take a look at this release [1]
- here's the AFX report [2] on the data
Links:
[1] http://www.fiercebiotech.com/press-releases/press-release-thrombogenics-presents-results-vitreomacular-traction-trial
[2] http://www.forbes.com/afxnewslimited/feeds/afx/2007/12/04/afx4400919.html